Brief: Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
14/05/2026 12:35
May 14 (Reuters) - Celcuity Inc CELC.O: CELCUITY’S PHASE 3 VIKTORIA-2 TRIAL OF GEDATOLISIB AS A FIRST-LINE TREATMENT FOR HR+/HER2- ADVANCED BREAST CANCER EXPANDING TO INCLUDE ENDOCRINE-SENSITIVE PATIENTS CELCUITY INC - VIKTORIA-2 TRIAL EXPANDS TO INCLUDE ENDOCRINE-SENSITIVE HR+/HER2- ADVANCED BREAST CANCER PATIENTS CELCUITY INC - HOLDS TYPE B MEETING WITH FDA ON AMENDED PHASE 3 TRIAL DESIGN CELCUITY INC - FDA GRANTS PRIORITY REVIEW TO CELCUITY'S NDA FOR GEDATOLISIB WITH PDUFA DATE JULY 17, 2026 CELCUITY INC - SUBMITS PATENT APPLICATION FOR SUBCUTANEOUS FORMULATION OF GEDATOLISIB Source text: ID:nGNXXDcnS Further company coverage: CELC.O ((Reuters.Briefs@thomsonreuters.com;))